Genpharmasec share news and announcements

BSE: 531592Commercial Services & SuppliesSmall Cap

₹0.99₹0.03 (2.94%)

Share price at the BSE close on 23 Oct 2026. Previous close ₹1.02.

52-week range of traded prices to 23 Oct 2026

₹0.75Low, 30 Mar 2026₹1.84High, 27 Oct 2025

Market cap: ₹55 Cr3,222nd largest listed
P/E: Earlier quarters restated in the year
P/B: 0.8
Dividend yield: Nonein the last 12 months
ROCE: −1.4%
Debt to equity: 0.50
Volume, BSE: 4,22,891

Genpharmasec share news and announcements

609 announcements, routine notices left out, newest first. Page 3 of 13.

Feb 2024
- 26 Feb · Disclosure
  Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sneha Sadhwani & Rajesh Sadhwani (opens in a new tab)
- 21 Feb · Announcement under Regulation 30 (LODR)-Allotment
  Outcome of Rights Issue committee held on 21st February, 2024 (opens in a new tab)
- 12 Feb · Reg. 32 - Not Applicable
  Reg. 32 - Statement of Deviation and Variation - Not Applicable (opens in a new tab)
- 12 Feb · Results
  Financial Results for quarter ended December 31, 2023. (opens in a new tab)
- 12 Feb · Board meeting
  Revised filing of Outcome of Board Meeting on February 12, 2024 (opens in a new tab)
- 12 Feb · Board meeting
  Outcome of Board meeting on February 12, 2024 for filing quarterly financial results (opens in a new tab)
- 8 Feb · Corporate action
  Outcome of Rights Issue Committee Meeting held today on 8th February, 2024 and the meeting concluded at 2:31 PM. (opens in a new tab)
- 5 Feb · Board meeting
  Meeting on 12 Feb 2024: quarterly results
- 5 Feb · Board meeting
  Meeting of the Board of Directors of the Company is scheduled on 12/02/2024 ,inter alia, to consider and approve 1. To consider and approve the .... (opens in a new tab)
Jan 2024
- 29 Jan · Business
  Company has formed a new wholly owned subsidiary Please find attached disclosure as under Regulation 30 of SEBI LODR Regulation 2015. (opens in a new tab)
- 20 Jan · Corporate action
  Outcome of Rights Issue Commitee held on January 20, 2024 (opens in a new tab)
- 9 Jan · Corporate action
  Outcome of the Rights Issue Committee Meeting for the Approval of Letter of Offer on 09th January, 2024. (opens in a new tab)
- 3 Jan · Corporate action
  Record Date intimation on 3rd January, 2024 (opens in a new tab)
- 3 Jan · Corporate action
  Outcome of Rights Issue Committee held on 03rd January, 2024 (opens in a new tab)
Dec 2023
- 11 Dec · Results
  Revised - financial results for the Board meeting held on 8th November, 2023 with the documents signed by the Whole-time Director of the Company and as complied with Reg. 33(2)(b). (opens in a new tab)
Nov 2023
- 8 Nov · Non-Applicability Of Regulation 32 Of SEBI (LODR), 2015 For The Quarter Ended September 30, 2023
  This is with the reference to abovementioned subject, that the Company is not having any unutilized issue proceeds. Therefore, the provisions of Reg. 32 of SEBI(LODR)Reg. 2015 is NOT APPLICABLE .... (opens in a new tab)
- 8 Nov · Results
  Pursuant to Reg. 30(2) of SEBI(LODR)Reg. 2015, we wish to inform you that the board meeting was held on 8-11-2023 to consider and approve the following : i) the un-audited financial .... (opens in a new tab)
- 8 Nov · Board meeting
  Pursuant to the provisions of Regulation 30 (2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform your .... (opens in a new tab)
- 1 Nov · Board meeting
  Meeting on 8 Nov 2023: quarterly results
- 1 Nov · Board meeting
  Meeting of the Board of Directors of the Company is scheduled on 08/11/2023 ,inter alia, to consider and approve 1. To consider & approve the un-audited .... (opens in a new tab)
Oct 2023
- 23 Oct · Corporate action
  Re-vise filing of outcome of Board Meeting held on October, 2023. This is further to the Board Meeting held on 5th June, 2023, approving the issue of equity shares by way rights issue to .... (opens in a new tab)
- 23 Oct · Corporate action
  This is further to the meeting of board of directors held on 5th June, 2023, approving the issue of equity shares by way of rights issue to the existing shareholders of the Company for .... (opens in a new tab)
Sep 2023
Aug 2023
- 31 Aug · Board meeting
  1. Considered and approved the Board Report for the year ended 31st March, 2023. 2. Considered and approved the notice of 31st Annual General meeting of the Members of the Company, which .... (opens in a new tab)
- 11 Aug · Non-Applicability Of Regulation 32 Of SEBI (LODR), 2015 For The Quarter Ended June 30, 2023
  This is with reference to Reg. 32, to be noted that the Company is not having any unutilized issue proceeds. Therefore, the provisions of Reg. 32 of SEBI(LODR) Reg. 2015 are Not - Applicable .... (opens in a new tab)
- 11 Aug · Results
  Pursuant to Reg. 30(2) of SEBI(LODR) Reg, 2015 we wish to inform you that the financial results are declared on 11th August, 2023 on Friday has: Considered and approved the un-audited .... (opens in a new tab)
- 11 Aug · Results
  Pursuant to the provisions of Regulation 30 (2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform your .... (opens in a new tab)
- 3 Aug · Board meeting
  Meeting on 11 Aug 2023: quarterly results
- 3 Aug · Board meeting
  Meeting of the Board of Directors of the Company is scheduled on 11/08/2023 ,inter alia, to consider and approve 1. To consider & approve the un-audited .... (opens in a new tab)
Jul 2023
- 14 Jul · I.E. Intimation Of Incorporation Of Subsidiary Company
  Pursuant to reg. 30 of SEBI(LODR) reg, 2015 as amended from time to time, we would like to inform you that the Company has incorporated a foreign Subsidiary Company Namely 'GENPHARMASEC .... (opens in a new tab)
Jun 2023
May 2023
- 30 May · Board meeting
  Meeting on 5 Jun 2023
- 30 May · Board meeting
  Meeting of the Board of Directors of the Company is scheduled on 05/06/2023 ,inter alia, to consider and approve the proposal for raising of funds .... (opens in a new tab)
- 26 May · Results
  1. Considered & Approved the Audited Financial Results (Standalone) for the quarter and year ended 31.03.2023. (Enclosed); 2. Considered & Approved the Audit Report (Standalone) issued .... (opens in a new tab)
- 26 May · For The Year Ended March 31, 2023
  1. Considered & Approved the Audited Financial Results (Standalone) for the quarter and year ended 31.03.2023. (Enclosed); 2. Considered & Approved the Audit Report (Standalone) .... (opens in a new tab)
- 18 May · Board meeting
  Meeting on 26 May 2023: audited results
- 18 May · Board meeting
  Meeting of the Board of Directors of the Company is scheduled on 26/05/2023 ,inter alia, to consider and approve 1. To consider & approve the Audited .... (opens in a new tab)
- 10 May · Meeting
  Notice of EOGM and .... (opens in a new tab)
- 9 May · Constitution Of Administrative Committees Of The Board
  Pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we would like to inform you that Board of Directors .... (opens in a new tab)
- 9 May · Meeting
  Board has fixed i.e. 26th May, 2023 as the 'Cut Off Date' for determining the eligibility of the Member to Vote by Electronic means. Further, pursuant to Regulation 42 of SEBI (Listing .... (opens in a new tab)
- 8 May · Board meeting
  Read with Schedule III of the said Regulations, we inform you that the Board of .... (opens in a new tab)

Genpharmasec share news and announcements

Feb 2024

Jan 2024

Dec 2023

Nov 2023

Oct 2023

Sep 2023

Aug 2023

Jul 2023

Jun 2023

May 2023